Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
Crohn's disease has several phenotypes (inflammatory, stricturing, fistulizing) and location
(small bowel, ileocecal, colon, and perianal). Approximately one third of patients have
inflammation limited to the colon. Up to two thirds will become medically refractory and
require a total abdominal colectomy for symptom control. The purpose of this study is to
determine the safety and efficacy of using allogeneic bone marrow derived mesenchymal stem
cells (MSCs) delivered by targeted endoscopic delivery to treat people for medically
refractory Crohn's colitis.